These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1909536)

  • 21. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.
    Diamond A; Prevor MB; Callender G; Druin DP
    Monogr Soc Res Child Dev; 1997; 62(4):i-v, 1-208. PubMed ID: 9421921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients.
    Bartus A; Palasti F; Juhasz E; Kiss E; Simonova E; Sumanszki C; Reismann P
    Metab Brain Dis; 2018 Oct; 33(5):1609-1615. PubMed ID: 29948654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurological manifestations in adults with phenylketonuria: new cases and review of the literature.
    Jaulent P; Charriere S; Feillet F; Douillard C; Fouilhoux A; Thobois S
    J Neurol; 2020 Feb; 267(2):531-542. PubMed ID: 31701331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dietary phenylalanine restriction on visual attention span in mentally retarded subjects with phenylketonuria.
    Giffin FD; Clarke JT; d'Entremont DM
    Can J Neurol Sci; 1980 May; 7(2):127-31. PubMed ID: 7407718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Chinese family with phenylketonuria and maternal phenylketonuria detected by family screening.
    Hsiao KJ; Chen CH; Chiu PC; Huang SC; Wuu KD
    Eur J Pediatr; 1986 Oct; 145(5):409-12. PubMed ID: 3792388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive functioning in adults with phenylketonuria: results of a long term study.
    Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R
    Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Undiagnosed maternal phenylketonuria: own clinical experience and literature review.
    Bouchlariotou S; Tsikouras P; Maroulis G
    J Matern Fetal Neonatal Med; 2009 Oct; 22(10):943-8. PubMed ID: 19557660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenylalanine-restricted diet should be life long. A case report on long-term follow-up of an adolescent with untreated phenylketonuria.
    Merrick J; Aspler S; Schwarz G
    Int J Adolesc Med Health; 2003; 15(2):165-8. PubMed ID: 12955819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agoraphobia in phenylketonuria.
    Waisbren SE; Levy HL
    J Inherit Metab Dis; 1991; 14(5):755-64. PubMed ID: 1779621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenylketonuria does not cause cataracts.
    Pitt DB; O'Day J
    Eur J Pediatr; 1991 Jul; 150(9):661-4. PubMed ID: 1915521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum tyrosine in children with phenylketonuria and mild hyperphenylalaninemia].
    Cabalska B; Nowacka M; Laskowska-Klita T; Nowaczewska I; Zorska K; Taljański W
    Med Wieku Rozwoj; 2000; 4(1):5-12. PubMed ID: 11013857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fasting serum phenylalanine in untreated institutionalised patients with phenylketonuria.
    Güttler F; Wamberg E
    J Ment Defic Res; 1977 Mar; 21(1):55-62. PubMed ID: 864699
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-Term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study.
    Jahja R; van Spronsen FJ; de Sonneville LMJ; van der Meere JJ; Bosch AM; Hollak CEM; Rubio-Gozalbo ME; Brouwers MCGJ; Hofstede FC; de Vries MC; Janssen MCH; van der Ploeg AT; Langendonk JG; Huijbregts SCJ
    Behav Genet; 2017 Sep; 47(5):486-497. PubMed ID: 28776207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet.
    Lee PJ; Amos A; Robertson L; Fitzgerald B; Hoskin R; Lilburn M; Weetch E; Murphy G
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):631-5. PubMed ID: 19204028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New variant of phenylketonuria with progressive neurological illness unresponsive to phenylalanine restriction.
    Smith I; Clayton BE; Wolff OH
    Lancet; 1975 May; 1(7916):1108-11. PubMed ID: 49470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A neuropsychiatric perspective of phenylketonuria I: overview of phenylketonuria and its neuropsychiatric sequelae.
    Bone A; Kuehl AK; Angelino AF
    Psychosomatics; 2012; 53(6):517-23. PubMed ID: 23157991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long term studies of untreated phenylketonuria II: the plasma phenylalanine level.
    Partington MW
    Neuropadiatrie; 1978 Aug; 9(3):255-67. PubMed ID: 581401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach.
    Waisbren SE; Brown MJ; de Sonneville LM; Levy HL
    Acta Paediatr Suppl; 1994 Dec; 407():98-103. PubMed ID: 7766971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence of phenylketonuria in Thailand.
    Kietduriyakul V; Komkris V; Tongkittikul K; Leangphibul P
    J Med Assoc Thai; 1989 Sep; 72(9):516-9. PubMed ID: 2809457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: Effects across tasks and developmental stages.
    Romani C; Palermo L; MacDonald A; Limback E; Hall SK; Geberhiwot T
    Neuropsychology; 2017 Mar; 31(3):242-254. PubMed ID: 28240926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.